You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CASODEX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Casodex, and when can generic versions of Casodex launch?

Casodex is a drug marketed by Ani Pharms and is included in one NDA.

The generic ingredient in CASODEX is bicalutamide. There are twenty-nine drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the bicalutamide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Casodex

A generic version of CASODEX was approved as bicalutamide by ACCORD HLTHCARE on July 6th, 2009.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CASODEX?
  • What are the global sales for CASODEX?
  • What is Average Wholesale Price for CASODEX?
Summary for CASODEX
Drug patent expirations by year for CASODEX
Drug Prices for CASODEX

See drug prices for CASODEX

Recent Clinical Trials for CASODEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, San FranciscoPhase 1
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Phase 1
Radboud University Medical CenterPhase 2

See all CASODEX clinical trials

Pharmacology for CASODEX

US Patents and Regulatory Information for CASODEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ani Pharms CASODEX bicalutamide TABLET;ORAL 020498-001 Oct 4, 1995 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for CASODEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ani Pharms CASODEX bicalutamide TABLET;ORAL 020498-001 Oct 4, 1995 ⤷  Sign Up ⤷  Sign Up
Ani Pharms CASODEX bicalutamide TABLET;ORAL 020498-001 Oct 4, 1995 ⤷  Sign Up ⤷  Sign Up
Ani Pharms CASODEX bicalutamide TABLET;ORAL 020498-001 Oct 4, 1995 ⤷  Sign Up ⤷  Sign Up
Ani Pharms CASODEX bicalutamide TABLET;ORAL 020498-001 Oct 4, 1995 ⤷  Sign Up ⤷  Sign Up
Ani Pharms CASODEX bicalutamide TABLET;ORAL 020498-001 Oct 4, 1995 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for CASODEX

See the table below for patents covering CASODEX around the world.

Country Patent Number Title Estimated Expiration
Japan H059129 NEW THERAPEUTIC DRUG USING LH-RH OR AGONIST ⤷  Sign Up
Finland 83770 ⤷  Sign Up
Japan H02131462 ACYLANILIDE, PREPARATION THEREOF AND DRUG OR ANIMAL DRUG COMPOSITION HAVING ANTI-ANDROGEN ACTION ⤷  Sign Up
Spain 524392 ⤷  Sign Up
European Patent Office 0100172 AMIDE DERIVATIVES ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for CASODEX

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0100172 97C0010 Belgium ⤷  Sign Up PRODUCT NAME: BICALUTAMIDUM; NAT. REGISTRATION NO/DATE: 624 S 291 F 3 19961014; FIRST REGISTRATION: GB 12619/0102 19950223
0100172 SPC/GB95/015 United Kingdom ⤷  Sign Up
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.